Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis
Sophie Nagle, Yann Nguyen, Mary‐Jane Guerry, T. Quéméneur, Dimitri Titeca‐Beauport, Thomas Crépin, Rafik Mesbah, Idris Boudhabhay, G. Pugnet, Céline Lebas, A. Néel, Alexandre Karras, É. Hachulla, Juliette Woessner, Vincent Pestre, Raphaël Borie, S. Vinzio, Jean-Baptiste Gouin, Sara Melboucy‐Belkhir, R. Outh, Benjamin Subran, Mathieu Gerfaud-Valentin, S. Humbert, Philippe Kerschen, Y. Uzunhan, Tiphaine Goulenok, Maxime Beydon, N. Costedoat‐Chalumeau, Xavier Puéchal, Benjamin Terrier
Topics & Concepts
MedicineGranulomatosis with polyangiitisRituximabInternal medicineMicroscopic polyangiitisRegimenAnti-neutrophil cytoplasmic antibodyCyclophosphamideClinical endpointKidney diseaseVasculitisGastroenterologySurgeryRandomized controlled trialChemotherapyDiseaseLymphomaVasculitis and related conditionsSystemic Sclerosis and Related DiseasesSarcoidosis and Beryllium Toxicity Research